Diamyd Medical finalizing Phase 3 screening as GMP review progresses

Diamyd Medical said DIAGNODE-3, its registrational Phase 3 trial of Diamyd® in genetically defined (HLA DR3‑DQ2) recent‑onset type 1 diabetics aged 12–28, has randomized more than 290 participants across 57 clinics and will finish screening in the coming weeks; an interim efficacy analysis of roughly 170 evaluable patients at 15 months is scheduled for the end of March 2026 and uses stimulated C‑peptide as the endpoint aligned with FDA guidance. The study has passed multiple independent safety reviews and a futility analysis, and the FDA has granted Fast Track (Stages 1–3) and Orphan Drug status and accepted C‑peptide as a surrogate for accelerated approval, meaning a positive interim could materially de‑risk an accelerated BLA path. Separately, Diamyd’s 2,200 m² Umeå manufacturing site for recombinant GAD65 is under GMP review by the Swedish Medical Products Agency, a critical step to secure clinical‑grade and eventual commercial supply if the program progresses.

Analysis

Diamyd Medical's registrational Phase 3 DIAGNODE-3 has randomized more than 290 participants and will conclude screening in the coming weeks; an interim efficacy analysis of approximately 170 evaluable participants assessed at 15 months is scheduled for end-March 2026 using stimulated C-peptide as the primary endpoint. The trial enrolls 12–28 year olds with recent-onset Stage 3 type 1 diabetes carrying the HLA DR3-DQ2 genotype across 57 clinics in eight European countries and the US, targeting a genetically predefined subgroup that constitutes about 40% of patients in Europe and the US. The study has passed multiple independent safety reviews and a futility analysis to date, supporting continuation without protocol changes.

The FDA has granted Fast Track designation across Stages 1–3, Orphan Drug designation for Stage 3, and has confirmed C-peptide as an acceptable surrogate to support an accelerated approval pathway, meaning a favorable interim could materially de-risk an accelerated Biologics Licensing Application. The interim was designed with FDA feedback to preserve registrational integrity while enabling potential acceleration, so its outcome carries outsized regulatory and valuation implications. Market sentiment from the signals is moderately positive (0.45) with modest market-impact expectations (0.35), reflecting cautious optimism among stakeholders.

Manufacturing is a parallel gating item: Diamyd's 2,200 m2 Umeå facility for recombinant GAD65 is under formal GMP review by the Swedish Medical Products Agency, and GMP certification is required to produce clinical-grade and eventual commercial material. GMP approval and the March 2026 interim represent two near-term binary catalysts; failure on either front would materially delay regulatory progress and commercialization. Investors should note the interim cohort (≈170) is smaller than total randomized, which may limit statistical certainty and increase the chance of an inconclusive readout.

Key Decisions for Investors

• Monitor the March 2026 interim efficacy readout closely—a positive C-peptide result could materially derisk an accelerated BLA and justify increasing exposure, while a negative or inconclusive result should prompt immediate reassessment of positions
• Await confirmation of GMP certification for the Umeå facility before adding material new exposure because clinical-grade and commercial supply depend on regulatory approval of manufacturing
• Maintain a catalyst-driven, size-limited position with downside protection (options or stop-loss) until both the interim efficacy outcome and GMP decision are resolved, given the binary regulatory and manufacturing risks
• Track any further safety or futility updates and enrollment completion communications and be prepared to adjust conviction if additional negative findings emerge, since current continuity is supported only by prior reviews